Home / Health / Developing Countries Pay 1% of US Price for Gilead’s Sovaldi

Developing Countries Pay 1% of US Price for Gilead’s Sovaldi

Developing countries such as Egypt,
India and Brazil won discounts to compensate 1 percent of a $84,000
price Gilead Sciences Inc. (GILD:US) is charging U.S. patients for a new
hepatitis C drug. Wealthier countries such as Ukraine and China
may not be so lucky, according to Doctors Without Borders, the
nonprofit ubiquitous assist group.

Countries including Kenya, Mozambique, Iran and Burma also
negotiated a $900 cost for a 12-week march of Gilead’s
Sovaldi, Isabelle Meyer-Andrieux, an confidant during Doctors Without
Borders, pronounced currently during a liver illness assembly in London. The
medicine is typically given for 12 weeks.

Egypt has one of a world’s top rates of infection of
hepatitis C and has treated some-more than 350,000 patients during the
government’s responsibility over a final 6 years, pronounced Wahid Doss of
the National Hepatology and Tropical Medicine Institute in
Egypt. While Gilead asked Egypt for a aloft cost during first, the
country was means to win improved terms, Doss said.

“Egypt’s instance shows a energy of a open health
approach and a vast scale,” pronounced Stefan Wiktor, who leads
the World Health Organization’s tellurian hepatitis program. “One
of a reasons they were means to negotiate a revoke cost is
because they have a large program.”

“We are training a lot from Egypt and from Brazil — these
are a champions,” Meyer-Andrieux said. “But this is usually a
start. A vital regard for us is a cost for middle-income
countries” such as China and Ukraine, where 75 percent of the
global race lives today.

Patient Population

About 150 million people worldwide are putrescent with the
hepatitis C virus, according to a WHO, with about 2.7 million
in a U.S. The illness is transmitted by a blood and can
be symptomless for years before it starts to injure a liver,
leading to cancer, organ disaster and, eventually, a transplant.

Gilead’s pricing plan is modeled after a past
experience with HIV medicines, where pricing in a U.S. and
Europe has been opposite to what is charged in a developing
world, pronounced Gregg Alton, ubiquitous warn during Foster City,
California-based Gilead, a world’s biggest builder of HIV

“Gilead’s tellurian pricing indication is formed on a country’s
ability to pay,” Alton pronounced in an e-mail response to questions
last month.

In a apart talk final month, Alton said, Gilead is
“very committed to creation certain patients everywhere have access.
As for a cost in a U.S., ‘‘we consider a cost is fair. It’s
a one-time cost that is your lifetime cost.’’

The WHO yesterday called for ‘‘a accordant effort’’ by
various stakeholders to revoke a cost of a drug. In addition
to tiered pricing, intentional and mandatory licensing, where
generic-drug makers are given accede to furnish more
affordable versions of a medicine, can also assistance achieve
affordability, a WHO said.

Gilead has been criticized in a U.S. for a cost of the
new medicine, with pharmacy advantage managers and insurers
seeking to revoke a cost and members of Congress job on
the association to clear a cost structure.

To hit a contributor on this story:
Makiko Kitamura in London at
[email protected]

To hit a editors obliged for this story:
Phil Serafino at
[email protected]
Andrew Pollack, Bruce Rule

Article source: http://www.businessweek.com/news/2014-04-10/developing-countries-pay-1-percent-of-u-dot-s-dot-price-for-gilead-s-sovaldi

Scroll To Top